North America held the greatest revenue share of almost 30.0% in 2021, Because of the presence of major manufacturers of pharmaceuticals and medical equipment. One of the main causes of illness and mortality is the rising rate of drug addiction and related unfavorable drug reactions.
NEWARK, Del: As per Future Market Insights’ latest industry analysis, It is estimated that the Pharmacovigilance Market will grow, from US$ 6.28 billion in 2022 to US$ 24.32 billion in 2032. Throughout the course of the anticipated period, the market is anticipated to grow at a CAGR of 13.1%, according to FMI.
As per FMI’s analysis, the market is expected to register double-digit growth, experiencing an impressive CAGR throughout the forecast period. Historically, the market posted credible gains, surpassing US$ 6 billion in 2020, expanding at a CAGR of over 14%. Growth prospects were further heightened during the COVID-19 pandemic, as the scramble for new treatment approaches is prompting pharmaceutical companies to initiate clinical trials for the same.
Prominent pharmaceutical companies are forging long-term partnerships and service agreements with contract research organizations and business processing outsourcing units to enhance existing pharmacovigilance operations by virtue of cost reduction from drug delivery to post-marketing approvals. In April 2021, Thermo Fisher Scientific Inc. announced its plans to acquire Pharmaceutical Product Development (PPD) Inc. for a purchase price of US$ 17.4 billion, which will help enhance the latter’s pharmacovigilance portfolio expansion.
Request for a sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-1107
Key Takeaways from FMI’s Pharmacovigilance Market Study
- By phase of drug development, stage IV clinical trials pharmacovigilance solutions account for over 3 out of 4 applications
- Based on method type, targeted spontaneous reporting to make maximum use of pharmacovigilance solutions
- By service provider type, contract outsourcing to generate almost two out of five pharmacovigilance solutions uptake
- US experiencing robust pharmacovigilance solutions providers presence amid prevalence of good PV practices
- Forthcoming clinical trials for numerous drug candidates through 2021 to widen UK’s growth prospects
- India to emerge as an emerging pharmacovigilance hub amid growing trends of medical operations outsourcing
- China to experience growth on the back of recent amendments to render pharmacovigilance implementation stronger
“Rising prevalence of chronic and infectious ailments is prompting multiple pharmaceutical giants to initiate widespread clinical trials for potential drug molecules, generating a highly competitive environment and generating major revenue pools,” says the FMI analyst.
Competitive Landscape
Prominent pharmacovigilance solutions providers are relying on collaborating with prominent biopharmaceutical and pharmaceutical companies to offer their digital solutions to facilitate effective patient care solutions. Also, offering advanced solutions is another prominent strategy. Some prominent faces include F. Hoffmann- La Roche, GlaxoSmithKline Plc., Covance Inc., ICON Plc. and iGATE Corporation among others.
Covance Inc. is a prominent pharmacovigilance solutions providing, offering end-to-end PV services spanning clinical and post-marketing phases from medical contract centers to ICSRs to medical reviews to electronic regulatory submissions. The system helps track weekly, daily and monthly metrics for quality, productivity and efficiency.
In April 2020, ICON Plc. initiated efforts to enhance pharmacovigilance practices, considering the onset of COVID-19. A webinar conducted on this issue by the company called for key pharmaceutical companies to automate their workflows by installing proactive and dedicated intelligence processes, forging detailed business and continuity plans and a virtually globally distributed footprint.
Ask from Market Research Expert @
https://www.futuremarketinsights.com/ask-question/rep-gb-1107
More Insights on the Global Pharmacovigilance Market
In its latest report, FMI offers an unbiased analysis of the global pharmacovigilance market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of phase of drug development (preclinical studies, phase I, phase II, phase III and phase IV), type of methods (spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring and EHR mining), service type provider (in-house pharmacovigilance and contract outsourcing) and region (North America, Latin America, Europe, Asia-Pacific and Middle East & Africa).
Forecast for Segmentation
Why is the market for pharmacovigilance giving Phase-IV Clinical Trials more importance?
The phase IV (post-marketing) segment “caught the whole industry by storm in 2021, accounting for a revenue share of more than 75.0%.”
These procedures add an additional level of security to the drugs undergoing clinical trials. It is anticipated that the data acquired and assessed at this stage is of highest value due to the extensive drug testing on a large demographic patient group of the highest significance following the commercialization of the drug.
Why Are Large Investments Being Attracted to the Pharmacovigilance Industry by Targeted Spontaneous Reporting?
The largest portion in 2021, at almost 30%, was accounted for through spontaneous reporting.
This is due to the technique’s widespread application in the identification of new, serious, and unusual ADRs, as well as its efficiency and low cost. Another element influencing the segment’s quick growth is the pharmaceutical industries and regulatory authorities’ substantial usage of monitoring reports created using this methodology.
Key Players
- Accenture Plc.
- Bristol-Myers Squibb
- Clinquest Group B.V.
- Cognizant Technology Solutions
- Covance Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- ICON Plc
- iGATE Corporation
- iMED Global Corporation
- inVentiv Health Inc.
- Novartis AG
Request Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-1107
Pharmacovigilance Market – Key Segments Covered
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
Phase of Drug Development
- Preclinical Studies
- Phase I
- Phase II
- Phase III
- Phase IV
Type of Methods
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
Service Type Provider
- In-house Pharmacovigilance
- Contract Outsourcing
Geography
- North America (US and Canada)
- Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe)
- Asia-Pacific (China, India, ASEAN, Japan and Rest of APAC)
- Latin America (Brazil, Mexico and Rest of LATAM)
- Middle East & Africa (GCC, South Africa and Rest of MEA)
Read Full Report @
https://www.futuremarketinsights.com/reports/pharmacovigilance-market
Key Market Segments Covered in Pharmacovigilance Industry Research
- Introduction
1.1. Report Description
1.2. Research Methodology
1.3. Market Segmentation
- Executive Summary
- Global Market Dynamics
3.1. Introduction
3.2. Market Drivers
3.2.1. Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring
3.2.2. Rise in Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Activities
3.2.3. Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth
Explore FMI’s Extensive Coverage On Healthcare Domain:
3D Imaging Surgical Solution Market Size : The market for 3D imaging surgical solutions is anticipated to grow at an average CAGR of 6.2% to reach an estimated market value of US$ 264.6 Million by 2032. (2022-2032). In 2022, the market will generate US$ 137.2 Million in revenue.
3D Printed Medical Implants Market Demand : The global demand for 3D printed medical implants is expected to rise at a healthy CAGR of 12.5% to be valued at US$ 2,494.5 million by 2032.
Multiple Unit Pellet Systems Market Share : The market for multiple unit pellet systems (MUPS) was valued at US$ 3.48 billion in 2021 and is expected to reach US$ 5.07 billion by the end of 2032, growing at a CAGR of 3.5%. Extended-release dosage forms are expected to dominate the market in 2021 with a share of roughly 47.1%, according to a recent study.
Contact-Free Sleep Monitoring Systems Market : In 2022, the market for contact-free sleep monitoring devices is anticipated to be worth US$92.2 Million. At a CAGR of 8.1%, the market is anticipated to grow to 216.4 million.
Therapeutic Apheresis Market Growth : it is predicted that demand for therapeutic apheresis would increase at a CAGR of 6.8%. The therapeutic apheresis market share is anticipated to be worth US$ 2577.9 million in 2022 and US$ 5313 million by 2032.
About Future Market Insights, Inc :
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn | Twitter | Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
